Benign Hyperplasia of the Pituitary

This version of the course is no longer available.
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course . Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about (online CE course)
Benign Hyperplasia of the Pituitary

Pituitary hyperplasia is defined as an absolute increase in the number of one or more cell types of the adenohypophysis. The condition of hyperplasia manifests, or is associated with a pituitary enlargement that is detectable using diagnostic imaging. The characterized causes of benign, or non-cancerous hyperplasia include hyperstimulation and hypersecretion of neurotransmitters and hormones produced by the hypothalamus, and stimulation from hormones produced from peripheral endocrine tissues.
Hyperplasia is further characterized as physiologic, pathologic and iatrogenic.
Physiologic pituitary hyperplasia results from pregnancy, where prolactin-producing lactotrope cells are stimulated by the increase in progesterone and estrogens to maintain the viability of the implanted embryo.
Pathologic pituitary hyperplasia occurs in response to an end-organ failure, such as hypothyroidism where respond to insufficient circulating thyroid hormone by producing excess TSH.
Iatrogenic, or physician-induced pituitary hyperplasia is caused by the administration of stimulating factors that spur the overgrowth of cell lines in the adenohypophysis. One examples is prolonged use of estrogens in hormone replacement therapy, which may lead to increased prolactin production from an overgrowth of lactotropes.
Pituitary hyperplasia is believed to be underdiagnosed, with many findings discovered during brain imaging studies when evaluating head injuries, or during autopsy.